STUDY OF ORAL KETAMINE AS ANTIDEPRESSANT IN ADULTS WITH DEPRESSION

Main Article Content

SHANTHI. CH
RAMA NARSIMHA REDDY A
SURESH .A

Abstract

In this present work, we studied and assess the effectiveness of oral ketamine as antidepressant in adults with depression. This study was a pilot study & prospective study conducted in the Psychiatry department in Telangana for a period of 2 months. A total of 10 individuals willing to participate with written informed consent during the study period will be included in the study. This pilot study found oral ketamine to be safe and well tolerated, the findings also showed effectiveness of oral ketamine in treatment of depression, with 30%, 70% and 100% of patients showing response on day 3,7,10 respectively. Improvement of symptoms during initial periods of treatment with oral ketamine was transient but gradually over subsequent doses sustained improvement was observed. Adverse effects noted are nausea, vomting,headache,diginess,drowsiness,bitter taste, flouting like feeling, acute dissociation.

Downloads

Download data is not yet available.

Article Details

How to Cite
CH, S., NARSIMHA REDDY A, R., & .A, S. (2021). STUDY OF ORAL KETAMINE AS ANTIDEPRESSANT IN ADULTS WITH DEPRESSION. Innovat International Journal Of Medical & Pharmaceutical Sciences, 4(6). Retrieved from https://innovatpublisher.com/index.php/iijmps/article/view/165
Section
Original Article(s)

References

Andrade C. Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action. J Clin Psychiatry. 2017;78(4):e415–e419.

Andrade C. Ketamine for depression, 2: diagnostic and contextual indications. J Clin Psychiatry. 2017;78(5):e555–e558.

US Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. FDA

Andrade C. Oral ketamine for depression, 1: pharmacological considerations and clinical evidence. J Clin Psychiatry. 2019;80(2):19f12820.

Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214(1):20–26.

Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology (Berl). 2018;235(2):393–398.

Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? results of a double-blind controlled trial. J Affect Disord. 2018;235:236–241.

Al Shirawi MI, Kennedy SH, Ho KT, et al. Oral ketamine in treatment-resistant depression: a clinical effectiveness case series. J Clin Psychopharmacol. 2017;37(4):464–467.

Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord. 2016;204:1–8.

Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and